CBL Stock Overview
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America.
+ 2 more risks
Control Bionics Limited Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.14|
|52 Week High||AU$0.48|
|52 Week Low||AU$0.12|
|1 Month Change||-23.68%|
|3 Month Change||-27.50%|
|1 Year Change||-67.78%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-87.71%|
Recent News & Updates
|CBL||AU Medical Equipment||AU Market|
Return vs Industry: CBL underperformed the Australian Medical Equipment industry which returned -7.5% over the past year.
Return vs Market: CBL underperformed the Australian Market which returned -2.2% over the past year.
|CBL Average Weekly Movement||16.2%|
|Medical Equipment Industry Average Movement||10.1%|
|Market Average Movement||8.9%|
|10% most volatile stocks in AU Market||15.9%|
|10% least volatile stocks in AU Market||4.1%|
Stable Share Price: CBL is more volatile than 90% of Australian stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: CBL's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
Control Bionics Limited, together with its subsidiaries, engages in the research, development, commercialization, and sale of assistive communications technology systems in Australia and North America. The company offers NeuroNode Trilogy and NeuroNode3 systems that allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. It also provides Cosmos Connect, a device to control a range of devices, including wheelchairs, dining robots, and gaming systems; Uno Touch, a speech generating device; and other sensors for multiple applications.
Control Bionics Limited Fundamentals Summary
|CBL fundamental statistics|
Is CBL overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|CBL income statement (TTM)|
|Cost of Revenue||AU$1.98m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.067|
|Net Profit Margin||-126.72%|
How did CBL perform over the long term?See historical performance and comparison